Tumor-associated antigen recognized by the γδ CAR extracellular domain

The target named Tumor-associated antigen recognized by the γδ CAR extracellular domain is a descriptive classification rather than a single molecular entity. It refers to the diverse array of surface proteins targeted by chimeric antigen receptors (CARs) or natural recognition domains expressed in gamma-delta (γδ) T cells. γδ T cells are a unique subset of T lymphocytes that bridge innate and adaptive immunity, capable of recognizing tumor cells in a major histocompatibility complex (MHC)-unrestricted manner. In therapeutic development, these cells are engineered with CARs to target specific antigens such as CD20, CD70, or NKG2D ligands (MICA/B and ULBPs). Some advanced platforms also utilize the natural γδ T-cell receptor (TCR) or its extracellular components to target molecules like Butyrophilin 3A1 (BTN3A1), which is essential for the activation of specific γδ T-cell subsets. These therapies are particularly valued for their potential in allogeneic "off-the-shelf" applications, as γδ T cells exhibit low alloreactivity and a reduced risk of graft-versus-host disease (GvHD) compared to conventional αβ T cells. By combining the specificity of a CAR extracellular domain with the inherent anti-tumor properties of the γδ T-cell chassis, these therapies aim to overcome challenges such as tumor heterogeneity and the immunosuppressive microenvironment.

Other names

Gamma-delta CAR-T targetγδ CAR targetTumor-associated antigen (TAA)NKG2D ligandButyrophilin subfamily 3 member A1 (BTN3A1)

Chimeric antigen receptor (CAR) or T-cell receptor (TCR) mediated recognition and targeted lysis of tumor cells expressing specific surface antigens.